ES2062310T3 - Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado. - Google Patents

Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.

Info

Publication number
ES2062310T3
ES2062310T3 ES90203064T ES90203064T ES2062310T3 ES 2062310 T3 ES2062310 T3 ES 2062310T3 ES 90203064 T ES90203064 T ES 90203064T ES 90203064 T ES90203064 T ES 90203064T ES 2062310 T3 ES2062310 T3 ES 2062310T3
Authority
ES
Spain
Prior art keywords
stabilized
procedure
manufacturing
pharmaceutical preparation
stabilized aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90203064T
Other languages
English (en)
Inventor
Den Oetelaar Petrus Johann Van
Maria Martina Francisc Mentink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Application granted granted Critical
Publication of ES2062310T3 publication Critical patent/ES2062310T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE PRESENTAN PREPARACIONES ACUOSAS ESTABILIZADAS QUE CONTIENEN UN ANTIDEPRESIVO EN UNA MEZCLA CON COMPUESTO ESTABILIZANTES TALES COMO LA L-METIONINA, D-METIONINA O MEZCLAS DE ESTAS. LAS PREPARACIONES ESTABILIZADAS OFRECEN UNA MEJOR ESTABILIDAD CUANDO SE EXPONEN A LA LUZ, A TEMPERATURAS RELATIVAMENTE ALTAS, AL TIEMPO Y A LOS PEROXIDOS QUE OFRECEN UNA MAYOR DURACION DE ALMACENAMIENTO. LOS ANTIDEPRESIVOS ESTABILIZADOS INCLUYEN LA MIRTAZAPINA, LA MIANSAINA, LA SEPTILINA Y LA AMITRIPTILINA.
ES90203064T 1989-12-06 1990-11-20 Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado. Expired - Lifetime ES2062310T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP89203092 1989-12-06

Publications (1)

Publication Number Publication Date
ES2062310T3 true ES2062310T3 (es) 1994-12-16

Family

ID=8202518

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90203064T Expired - Lifetime ES2062310T3 (es) 1989-12-06 1990-11-20 Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.

Country Status (15)

Country Link
US (1) US5082864A (es)
EP (1) EP0431663B1 (es)
JP (1) JP2977912B2 (es)
KR (1) KR0185377B1 (es)
AT (1) ATE99943T1 (es)
AU (1) AU628768B2 (es)
CA (1) CA2030773C (es)
DE (1) DE69005992T2 (es)
DK (1) DK0431663T3 (es)
ES (1) ES2062310T3 (es)
FI (1) FI97689C (es)
IE (1) IE63985B1 (es)
NZ (1) NZ236332A (es)
PT (1) PT96096B (es)
ZA (1) ZA909568B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH1591H (en) * 1992-10-09 1996-09-03 Fulcher; John Preparation of flavor-enhanced reduced calorie fried foods
IL107887A (en) * 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
EP0813873B1 (en) * 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
ES2212550T3 (es) * 1998-04-02 2004-07-16 Akzo Nobel N.V. Solucion oral liquida que comprende el antidepresor mirtazapina.
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
WO2002064735A2 (en) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
BRPI0506829A (pt) * 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
US20060058390A1 (en) * 2004-09-14 2006-03-16 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
PT2135603E (pt) * 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
AU2007207606A1 (en) * 2006-01-17 2007-07-26 Regents Of The University Of Colorado Central administration of stable formulations of therapeutic agents for CNS conditions
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
KR101652081B1 (ko) 2014-12-30 2016-08-30 김인호 전극보일러 급탕시스템
JP6876003B2 (ja) 2015-02-27 2021-05-26 デクラ リミテッド イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置
KR20170001494A (ko) 2015-06-26 2017-01-04 김인호 전극보일러 전류제어시스템
CN108853042B (zh) * 2018-09-20 2021-03-26 北京哈三联科技有限责任公司 一种米氮平冻干口崩片及其制备方法和应用
GR1009883B (el) * 2019-06-07 2020-12-11 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας Και Αναπτυξης Α.Ε. Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν υδροχλωρικη νορτριπτυλινη

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2082910A (en) * 1980-08-28 1982-03-17 Berk Pharmaceuticals Ltd Anti-depressant compositions
US4603131A (en) * 1982-04-26 1986-07-29 Bernstein Joel E Method and composition for treating and preventing irritation of the mucous membranes of the nose
DE3247676A1 (de) * 1982-12-23 1984-06-28 A. Nattermann & Cie GmbH, 5000 Köln Galenische form fuer amitriptylinoxid und verfahren zur herstellung

Also Published As

Publication number Publication date
AU6779890A (en) 1991-06-13
PT96096B (pt) 1998-02-27
FI906008L (fi) 1991-06-07
IE63985B1 (en) 1995-06-28
FI97689C (fi) 1997-02-10
JP2977912B2 (ja) 1999-11-15
FI906008A0 (fi) 1990-12-05
EP0431663A1 (en) 1991-06-12
DE69005992D1 (de) 1994-02-24
CA2030773A1 (en) 1991-06-07
FI97689B (fi) 1996-10-31
JPH05262651A (ja) 1993-10-12
IE904226A1 (en) 1991-06-19
US5082864A (en) 1992-01-21
KR910011250A (ko) 1991-08-07
ATE99943T1 (de) 1994-01-15
ZA909568B (en) 1991-09-25
DK0431663T3 (da) 1994-03-07
DE69005992T2 (de) 1994-05-05
CA2030773C (en) 2001-07-24
KR0185377B1 (ko) 1999-05-01
AU628768B2 (en) 1992-09-17
EP0431663B1 (en) 1994-01-12
NZ236332A (en) 1992-07-28
PT96096A (pt) 1991-09-30

Similar Documents

Publication Publication Date Title
AU628768B2 (en) Stabilized solutions of psychotropic agents
ES2119984T3 (es) Nuevos compuestos propinil bi-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2159358T3 (es) Procedimiento para elaborar preparaciones de liposomas.
ES2149955T3 (es) Vesiculas con liberacion controlada de sustancias activas.
ES2140391T3 (es) Derivados de dialcoxi-piridinil-bencimidazol, procedimiento para su preparacion y su uso farmaceutico.
BR0215052A (pt) Composições acaricidas e métodos
ES2070252T3 (es) Composicion de resina de polipropileno resistente a la radiacion.
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
ES2055860T3 (es) Derivados 2-aminopirimidinona.
ES2185124T3 (es) Composiciones de teñido de las fibras queratinicas que contienen derivados de indazoles de amina y procedimiento de teñido.
ES2194935T3 (es) Preparados estables de transglutaminasa y procedimiento para su preparacion.
AR011734A1 (es) Analogos del peptido lh-rh, y composiciones farmaceuticas que los contienen
ES2074069T3 (es) Liposoma que contiene un nuevo fosfato como constituyente de la membrana, preparados liposomales y cosmeticos que contienen el fosfato.
ES2072839T3 (es) Procedimiento para la preparacion de un granulado con contenido en persulfatos para decolorar o enrubiar cabellos.
SV1998000119A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa. ref. lea 32671-sv
ES2038359T3 (es) Procedimiento para la obtencion de formulaciones inyectables intramusculares de inhibidores de girasa.
AR246160A1 (es) Preservativo para composiciones acuosas.
ES2004985A6 (es) Procedimiento de preparacion de 1-4aminofenil-4-metil-7,8-metilendioxi-3,4-dihidro-5h-2,3-benzodiazepina y sus sales de adicion acidas
ES2120145T3 (es) Compuestos bi-aromaticos acetilenados con grupo adamantilo, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2117474T3 (es) Derivados n-sustituidos del 4-hidroxiindol y composiciones de tinte de fibras queratinicas que los contienen.
ES2124069T3 (es) Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
DE50010978D1 (de) Kosmetische Stiftzubereitung
ES2130598T3 (es) Preparaciones cosmeticas y/o farmaceuticas.
ES2071458T3 (es) Nuevos compuestos amidicos de 1-(alcoxi-bencil)-piperacinas, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 431663

Country of ref document: ES